Active, Not Recruiting
To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy
NCT07098897
- Conditions
- Autoimmune Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
- Locations
-
- The First Affiliated hospital of Xuzhou Medical University Xuzhou, Jiangsu, China